Lead programs include PGN-EDO51 in Phase 2 for Duchenne muscular dystrophy (DMD) exon 51-skipping and PGN-EDODM1 in Phase 2 for myotonic dystrophy type 1. The company raised $115.0 million in September 2025 and held $163.7 million in cash, extending runway into H2 2027.
Cyborg Score Rationale
Recent FREEDOM trial showed mean splicing correction of 53.7% at 15 mg/kg with encouraging safety profile, and 5 mg/kg FREEDOM2 cohort readout expected Q1 2026. Company has strong cash position and validated platform technology but remains clinical-stage with execution risk.
Top Insights
Mean splicing correction of 53.7% achieved in lead program (FREEDOM 15 mg/kg cohort) with mild-to-moderate safety profile
Strong cash position of $163.7 million extends runway into H2 2027, reducing near-term financing risk
USPTO issued composition-of-matter patent for PGN-EDODM1 covering peptide-conjugated oligonucleotide chemistry and EDO platform design
EDO platform engineered to optimize tissue penetration, cellular uptake and nuclear delivery across multiple tissue types
Named Competitors
Antisense Oligonucleotide Therapies — Conventional antisense and exon-skipping therapies for neuromuscular diseases
Gene Therapy Approaches — Gene therapy and gene-modification approaches for muscular dystrophies
Recent Developments
(December 2025) Joseph Vittiglio appointed Chief Business and Legal Officer; USPTO issued patent for PGN-EDODM1
(September 2025) $115 million financing; Q3 2025 FREEDOM trial showed 53.7% mean splicing correction at 15 mg/kg
(2026) FREEDOM2 5 mg/kg readout expected Q1 2026; 10 mg/kg dosing planned Q1 2026 with results in H2 2026
Open the full interactive PepGen Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.